The Broad Institute of MIT and Harvard universities and Germany-based Bayer are introducing the Precision Cardiology Laboratory (PCL), it was reported on Monday.
The main aim of the PCL will be to pursue scientific insights aimed at developing new therapies for heart failure.
Research in the Precision Cardiology Laboratory will bring scientists from both organisations into a combined work space at the Broad Institute, effectively integrating Broad's innovative methods for basic scientific discovery and the clinical expertise of its practicing physician/researchers with Bayer's long history of drug development. The effort will be led by Broad Associate Member, Patrick Ellinor, who directs the Cardiac Arrhythmia Service at Massachusetts General Hospital and is a professor of medicine at Harvard Medical School.
The PCL's initial goal is to develop high-resolution, single-cell maps of cardiovascular tissues in human and animal models. Using tissue samples donated by healthy individuals as well as people suffering from cardiovascular disease, researchers will build datasets to accelerate insights into heart failure.
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal